CompaniesAngiotech Pharmaceuticals

Angiotech Pharmaceuticals

defunct
About

Defunct Company

Areas of Focus

Categories

Rebranded/RenamedBankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (12)
View all

Total Trials

12

As Lead Sponsor

11

As Collaborator

1

Total Enrollment

5,810

By Phase

PHASE2: 4PHASE3: 3PHASE1: 1NA: 2PHASE1/PHASE2: 1

By Status

COMPLETED: 6UNKNOWN: 4TERMINATED: 2
Clinical Trials Pipeline12 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Today
NCT00677222
Hover over trial bars to see details

Recent Trials

NCT05629598Lead Sponsor
A Study of PEG-EPO Injection (CHO Cells) for Maintenance Therapy of Patients With Renal Anemia .
PHASE2Unknown
150 participants
Started: Apr 13, 2022 · Completed: Aug 16, 2023
NCT05295173Lead Sponsor
A Study of r-PA Treating Patients With Acute Ischemic Stroke（RAISE）
PHASE3Completed
1,412 participants
Started: Mar 21, 2022 · Completed: Jun 22, 2023
NCT04110275Lead Sponsor
Injection of Recombinant Human Tissue-type Plasminogen Activator Derivative for Acute Pulmonary Embolism(rPA)
PHASE2Unknown
174 participants
Started: Oct 31, 2019 · Completed: Aug 31, 2021
NCT04028518Lead Sponsor
A PhaseⅡ of Injection for Recombinant Human Tissue Plasminogen Kinase Derivative in Treatment of Acute Ischemic Stroke.
PHASE2Unknown
180 participants
Started: Jul 20, 2019 · Completed: Mar 31, 2021
NCT03049774Lead Sponsor
A Study of the Recombinant Human Interleukin-11 (I) (Baijieyi) for Prevention and Treatment of Chemotherapy-induced Thrombocytopenia in Patients With Malignant Tumor
N/AUnknown
2,000 participants
Started: Feb 28, 2017 · Completed: Dec 31, 2017
View all 12 trials →